O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUSCésar Serrano,Michael Heinrich,Suzanne George,John Zalcberg,Sebastian Bauer, Hans Gelderblom,Patrick Schöffski,Robin L. Jones,Steven Attia,Gina Z. D'Amato,Ping Chi,Peter Reichardt,Julie Meade,Vienna Reichert,K. Shi,J.-Y. Blay,M. von MehrenANNALS OF ONCOLOGY（2020）引用 4|浏览45暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
